Greenleaf Trust grew its stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 219.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,142 shares of the financial services provider's stock after acquiring an additional 11,780 shares during the quarter. Greenleaf Trust's holdings in CME Group were worth $4,548,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of the stock. Norges Bank acquired a new position in CME Group in the 4th quarter worth approximately $1,107,389,000. Price T Rowe Associates Inc. MD increased its holdings in CME Group by 89.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider's stock worth $1,923,047,000 after buying an additional 3,921,278 shares during the period. GAMMA Investing LLC increased its holdings in CME Group by 32,941.0% in the 1st quarter. GAMMA Investing LLC now owns 1,858,887 shares of the financial services provider's stock worth $493,144,000 after buying an additional 1,853,261 shares during the period. Egerton Capital UK LLP acquired a new position in CME Group in the 4th quarter worth approximately $223,967,000. Finally, Franklin Resources Inc. boosted its position in CME Group by 38.7% in the 4th quarter. Franklin Resources Inc. now owns 3,366,786 shares of the financial services provider's stock worth $781,869,000 after purchasing an additional 939,679 shares in the last quarter. Institutional investors and hedge funds own 87.75% of the company's stock.
Insider Buying and Selling
In other CME Group news, General Counsel Jonathan L. Marcus sold 390 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $277.50, for a total value of $108,225.00. Following the transaction, the general counsel directly owned 6,708 shares of the company's stock, valued at $1,861,470. This trade represents a 5.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Phyllis M. Lockett sold 1,060 shares of the firm's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $277.88, for a total value of $294,552.80. Following the completion of the sale, the director directly owned 3,108 shares of the company's stock, valued at $863,651.04. This trade represents a 25.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,400 shares of company stock worth $3,680,610 in the last 90 days. Corporate insiders own 0.30% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have commented on CME. Royal Bank Of Canada restated a "sector perform" rating and issued a $269.00 price objective on shares of CME Group in a research report on Thursday, April 3rd. Piper Sandler upped their price objective on CME Group from $275.00 to $283.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 8th. Morgan Stanley upped their price objective on CME Group from $301.00 to $304.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Citigroup upped their price objective on CME Group from $265.00 to $275.00 and gave the stock a "neutral" rating in a research report on Thursday, July 3rd. Finally, Bank of America upped their price objective on CME Group from $200.00 to $219.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 2nd. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $259.87.
Read Our Latest Stock Report on CME
CME Group Price Performance
Shares of NASDAQ:CME traded up $0.01 during trading on Wednesday, reaching $275.64. The stock had a trading volume of 2,841,477 shares, compared to its average volume of 2,196,408. The business has a fifty day moving average price of $276.76 and a 200-day moving average price of $258.61. CME Group Inc. has a 1-year low of $193.17 and a 1-year high of $290.79. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02. The stock has a market cap of $99.33 billion, a PE ratio of 27.73, a PEG ratio of 3.83 and a beta of 0.44.
CME Group (NASDAQ:CME - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.61 by $0.19. The company had revenue of $1.64 billion for the quarter, compared to analysts' expectations of $1.56 billion. CME Group had a net margin of 57.71% and a return on equity of 14.03%. The firm's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.50 EPS. On average, equities analysts forecast that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.
CME Group Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Investors of record on Monday, June 9th were paid a dividend of $1.25 per share. The ex-dividend date was Monday, June 9th. This represents a $5.00 annualized dividend and a yield of 1.81%. CME Group's dividend payout ratio is presently 50.30%.
About CME Group
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Read More

Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report